vimarsana.com

Page 94 - ஸ்டான்போர்ட் பல்கலைக்கழகம் பள்ளி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The New Beyond Burger Is About to Launch Here s What Is Different

Shares Starting May 3, Beyond Meat will roll out the newest version of its vegan Beyond Burger at retailers nationwide. The new iteration of the plant-based burger aims to better compete with animal-derived beef in a number of ways. The new Beyond Burger has 35 percent less saturated fat (and 35 percent less overall fat) than an 80/20 beef patty. The new patty is fortified with B vitamins and minerals comparable to the nutritional profile of beef. Whereas the brand’s original Beyond Burger was sold in two-patty packs, the new iteration will be available in both two-patty packs and bulk four-patty packs ($9.99) to better compete with the price of beef. The new vegan meat will also be offered as a one-pound Beyond Beef pack later this summer. 

Vadadustat Matches Standard for CKD-Related Anemia, With Caveat

email article The investigational hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor vadadustat was noninferior to the erythropoiesis-stimulating agent darbepoetin alfa for treating anemia in chronic kidney disease (CKD) patients, a pair of phase III trials found. 2TECT Study of non-dialysis-dependent CKD treatment with vadadustat met the pre-specified noninferiority endpoint for hematologic efficacy compared with darbepoetin alfa, reported Glenn Chertow, MD, MPH, of Stanford University School of Medicine in California, and colleagues. Looking only at ESA-untreated patients, there was an average between-group hemoglobin concentration difference of 0.05 g/dL (95% CI -0.04 to 0.15) maintained from weeks 24 to 36 with vadadustat or darbepoetin alfa treatment.

COVID-19 may result in prolonged infection in immunocompromised children and young adults

 E-Mail Children and young adults with compromised immune systems, such as those undergoing cancer treatment, may experience a prolonged period of infection with SARS-CoV-2, the virus that causes COVID-19, and the extended duration of infection may increase the incidence of mutations. This case study was conducted by investigators at Children s Hospital Los Angeles and is published in the journal Most people are infectious for about 10 days after first showing COVID-19 symptoms. In this study, researchers describe two children and a young adult with acute lymphoblastic leukemia who tested positive for SARS-CoV-2 for months. This is the first report of prolonged infection in a pediatric or young adult population.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.